Does Dicyclomine Cause Constipation?
Yes, dicyclomine causes constipation as a direct consequence of its anticholinergic mechanism of action, which reduces gastrointestinal motility and tone. This is explicitly documented in FDA labeling and clinical guidelines, making it a predictable and common side effect that clinicians must anticipate when prescribing this medication.
Mechanism and Evidence
Dicyclomine is an anticholinergic antispasmodic that works by inhibiting muscarinic receptors in the autonomic nervous system. The FDA drug label explicitly states that dicyclomine causes "reduction in the tone and motility of the gastrointestinal tract leading to constipation" 1. This is not an idiosyncratic reaction but rather a pharmacological consequence of blocking muscarinic receptors that normally stimulate intestinal motility.
The 2016 NCCN Palliative Care Guidelines confirm this mechanism, categorizing dicyclomine among "anticholinergic drugs (antidepressants, antispasmodics, phenothiazines, and haloperidol)" that are known to cause constipation 2.
Clinical Significance
When to Avoid Dicyclomine
British Society of Gastroenterology guidelines (2000) specifically recommend that tricyclic antidepressants with similar anticholinergic properties "are best avoided if constipation is a major feature" 3. While this statement refers to tricyclics, the same principle applies to dicyclomine given its anticholinergic mechanism.
The constipation risk is particularly relevant because:
- Dicyclomine is often prescribed for IBS, where constipation may already be a predominant symptom
- In IBS-C (constipation-predominant IBS), using dicyclomine could worsen the primary complaint
- The 2021 BSG guidelines note that antispasmodics with anticholinergic action like dicyclomine showed "the most significant improvement in pain" but "the common side effect of dry mouth may limit their use" 4 - constipation follows similar logic
Documented Frequency
In a clinical trial evaluating dicyclomine for reducing MRI artifacts, constipation was listed among the "most frequently" reported adverse effects, though it was considered minor 5. The FDA label lists constipation under gastrointestinal disorders in postmarketing surveillance 1.
Clinical Algorithm for Use
Use dicyclomine when:
- Patient has IBS with diarrhea (IBS-D) or mixed type (IBS-M)
- Abdominal pain/cramping is the predominant symptom
- Constipation is NOT a major feature
Avoid or use with extreme caution when:
- Patient has IBS-C (constipation-predominant)
- Pre-existing constipation is present
- Patient is elderly (more susceptible to anticholinergic effects) 1
- Patient is taking other constipating medications (opioids, other anticholinergics)
If constipation develops:
- Consider dose reduction (efficacy may be maintained at lower doses)
- Add prophylactic stimulant laxatives if continuing dicyclomine is necessary
- Consider switching to non-anticholinergic antispasmodics (mebeverine, alverine) that have direct smooth muscle effects 4, 6
Important Caveats
The anticholinergic effects are dose-dependent and usually reversible upon discontinuation 1. However, in severe cases, dicyclomine can contribute to serious complications like toxic megacolon in patients with ulcerative colitis or intestinal pseudo-obstruction (Ogilvie's syndrome) 1. The FDA label explicitly contraindicates dicyclomine in severe ulcerative colitis for this reason.
The 2022 AGA guidelines note that while antispasmodics including dicyclomine show benefit for IBS symptoms, "it is not known whether antispasmodics are more efficacious in specific IBS subtypes, but its regular use in constipation may be limited due to its anticholinergic effects" 6.